Pharmaceutical
Jazz Pharmaceuticals Receives NICE Recommendation For The Reimbursement Of Epidyolex (Cannabidiol) For The Treatment Of Seizures Associated With Tuberous Sclerosis Complex In England
PRESS RELEASE JAZZ Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Epidyolex® (cannabidiol,100 mg/mL oral solution), developed by GW Pharmaceuticals (“GW”;
BusinessCann
February 1, 2023
